Ashish D. Pal, President Director at MSD Indonesia, discusses the importance of introducing innovative pharmaceuticals, vaccines and biologics to address significant unmet needs and the strategic importance of the universal healthcare coverage program (JKN) towards meeting the national healthcare goals.
Mr. Pal, you have been leading the Indonesian affiliate of MSD since January 2015. How have the operations of the affiliate evolved under your tenure and what have been your biggest accomplishments in Indonesia?
"Our innovative cancer medicine gives physicians a new therapeutic option and hope in managing the tens of thousands of lung cancer patients across the country."
